Watch Repligen's Q3 2026 earnings call for the expected financial impact of the acquisition on 2026 outlook, including any revenue synergy targets and integration costs. The deal's success hinges on cross-selling BioLife's products through Repligen's Asia Pacific channel.
Price Chart
Executive Summary
Repligen completed its acquisition of BioLife Solutions, paying $11.25 per share in cash plus 0.1442 shares of Repligen common stock. The deal expands Repligen's presence in the cell therapy market with BioLife's high-margin consumables and biopreservation media portfolio, including CryoStor, which supports 18 approved therapies. Repligen will provide financial impact details on its Q3 2026 earnings call.
Key Facts
- Acquisition of BioLife Solutions completed for $11.25 per share in cash plus 0.1442 shares of Repligen common stock per BioLife share.
- BioLife's CryoStor biopreservation media supports 18 commercially approved therapies and the majority of U.S. commercial cell-based therapy trials.
- Combined entity expected to benefit from Repligen's global reach and BioLife's customer relationships.
- Repligen to provide 2026 financial outlook impact on Q3 2026 earnings call.
Financial Impact
Deal value not explicitly stated; per-share consideration is $11.25 cash plus 0.1442 RGEN shares. BioLife's high-margin consumables business adds recurring revenue to Repligen's cell therapy offering.
Risk Factors
- Integration risks and potential dilution from the stock component of the consideration.
- Cell therapy market growth may not materialize as expected, impacting the deal's strategic rationale.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3375610 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | — | awaiting T+60 | — | — |
Oct 27, 2026 today | Press Release | $181.38 | awaiting T+60 | — | $180.17 (−0.67%) |
Oct 15, 2026 11d ago | Institutional Cluster | $184.17 | awaiting T+60 | — | $180.17 (−2.17%) |
Oct 7, 2026 19d ago | SC 13G/A | $167.22 | awaiting T+60 | — | $180.17 (+7.74%) |
Oct 6, 2026 20d ago | 8-K | $174.86 | awaiting T+60 | — | $180.17 (+3.04%) |
Oct 6, 2026 20d ago | Press Release | $174.86 | awaiting T+60 | — | $180.17 (+3.04%) |
Aug 24, 2026 9w ago | S-4 | $181.69 | awaiting T+60 | — | $180.17 (−0.84%) |
Jul 28, 2026 12w ago | 8-K | $145.34 $180.01 | ▲ +23.85% | ▲ +19.50% | $180.17 (+23.96%) |
Jul 22, 2026 13w ago | 425 / 8-K | $140.09 $184.17 | ▲ +31.47% | ▲ +28.20% | $180.17 (+28.61%) |
Jul 22, 2026 13w ago | Press Release | $140.09 $184.17 | ▲ +31.47% | ▲ +28.20% | $180.17 (+28.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers